

阿替普酶静脉溶栓治疗急性脑梗死对血清 VE-cadherin 的影响

胡新平

吉林市中心医院 吉林 132000

【摘要】目的: 2020 年 8 月至 2021 年 12 月, 98 例急性脑梗死 (ACI) 患者被随机分为观察组 (49 例) 和对照组 (49 例)。观察组接受阿替普酶 (rt-PA) 静脉溶栓治疗, 对照组接受常规治疗。结果: 观察组炎症因子、血液流变学指标、MCP-1、脑损伤血清指标和 VE-cadherin 水平均低于对照组 ($P < 0.05$)。颅内血流动力学水平观察组高于对照组 ($P < 0.05$)。结论: rt-PA 静脉溶栓治疗可有效提高 ACI 患者血清 VE-cadherin 水平, 保护神经功能和血管内皮功能, 改善治疗效果。

【关键词】: VE-cadherin

Influence of Alteplase Intravenous Thrombolysis on Serum VE-cadherin in Acute Cerebral Infarction

Xinping Hu

Jilin Central Hospital Jilin 132000

Abstract: Objective: To analyze the effect of intravenous thrombolysis with alteplase (rt-PA) on serum VE-cadherin in patients with acute cerebral infarction (ACI). Methods: Ninety-eight patients with ACI from August 2020 to December 2021 were randomly divided into observation group and control group, with 49 cases in each group. They were treated with rt-PA intravenous thrombolysis and conventional therapy respectively, and the effects were compared. Results: The levels of inflammatory factors, hemorheology indexes, MCP-1, serum indexes of brain injury and VE-cadherin in the observation group were lower than those in the control group ($P < 0.05$). The level of intracranial hemodynamics in the observation group was higher than that in the control group ($P < 0.05$). Conclusion: rt-PA intravenous thrombolysis can effectively improve the level of serum VE-cadherin in ACI, protect the nerve function and vascular endothelial function, and improve the curative effect.

Keywords: VE-cadherin; Hemorheology; Apase; Acute cerebral infarction; Intravenous thrombolytic therapy; Intracranial hemodynamics

ACI

rt-PA

1 资料和方法

1.1

98 例 ACI 患者于 2020 年 8 月至 2021 年 12 月被随机分为观察组 (49 例) 和对照组 (49 例)。观察组接受阿替普酶 (rt-PA) 静脉溶栓治疗, 对照组接受常规治疗。结果: 观察组炎症因子、血液流变学指标、MCP-1、脑损伤血清指标和 VE-cadherin 水平均低于对照组 ($P < 0.05$)。颅内血流动力学水平观察组高于对照组 ($P < 0.05$)。结论: rt-PA 静脉溶栓治疗可有效提高 ACI 患者血清 VE-cadherin 水平, 保护神经功能和血管内皮功能, 改善治疗效果。

ACI

rt-PA

ACI

ACI

H63020201 100mg

H20113232 75mg

H19990258 20mg 1

30mg H20050280

100ml 2 2
21
rt- PA 4.5h P>0.05 P<0.05
0.9mg/kg rt- PA Boehringer Ingelheim 1
Pharma Gmb H&Co.KG 90mg 1
10% 1min 90% 1h
CT 24h
1.3 15d
1 IL-1
- TNF- C CRP 2
3
Hcy S-100
NSE 4 Vm Vd
Vp^[4] 5 1 MCP-1
VE-cadherin^[5]
1.4
SPSS21.0 P 0.05
2

		$\bar{x} \pm s$					
		IL-1	pg/ml	TNF-	ng/L	CRP	mg/L
4	9	97.81	41.61	60.13	26.66	44.93	18.74
		\pm	\pm	\pm	\pm	\pm	\pm
		12.34	4.02	9.36	2.07	5.00	1.96
4	9	98.10	61.53	60.28	38.44	45.43	33.55
		\pm	\pm	\pm	\pm	\pm	\pm
		12.55	5.51	9.51	3.80	5.55	3.59
t		0.552	5.145	0.142	5.362	0.336	6.302
P		>0.05	<0.05	>0.05	<0.05	>0.05	<0.05

		2		$\bar{x} \pm s$		2		2	
		(%)		(mPa/s)		(mPa/s)		(mPa/s)	
49		47.90 \pm 5.63	34.97 \pm 4.63	1.91 \pm 0.30	1.05 \pm 0.22	18.75 \pm 3.04	10.03 \pm 2.06	7.78 \pm 0.81	5.25 \pm 0.50
49		47.81 \pm 5.8	39.81 \pm 4.38	1.94 \pm 0.25	1.51 \pm 0.26	18.88 \pm 3.26	14.92 \pm 2.30	7.80 \pm 0.78	6.53 \pm 0.60
t		0.412	5.142	0.321	5.268	0.536	5.142	0.335	5.369
P		>0.05	<0.05	>0.05	<0.05	>0.05	<0.05	>0.05	<0.05

3 讨论

ACI

ACI

rt- PA

^[6] ACI

ACI

^[7] ACI

ACI

ACI

Na⁺ - K⁺

IL-1 CRP TNF-

rt- PA

ACI

ACI

rt- PA

[J]. ,2021,49(7):806- 808.

[3] , , , . [J]. , 2021,35(3): 301- 305.

ACI rt- PA 4.5h [J]. , 2021 (27):83.

ACI rt- PA [5] .

VE- cadherin [J]. (),2021, 21(4): 218- 219.

参考文献:

[1] , , , . [J]. ,2021, 29(8):67- 68.

[2] , , , . [7] , , . [J]. ,2021, 27(5):1027- 1031,1036.